Exploiting vitamin C as a prooxidant to activate ROS-responsive prodrugs for potent and selective tumor killing.

For instance, a phase I/II trial in metastatic pancreatic cancer patients reported that high-dose intravenous vitC combined with gemcitabine and erlotinib was safe and associated with a positive trend in overall survival compared to historical controls [ 46 , 53 , 56 ].

also in 11,005 other papers